[Results of kidney transplantation in Krakow in 1992-2000]

Przegl Lek. 2000;57(11):619-23.
[Article in Polish]

Abstract

The aim of the study was an analysis of renal transplantation results in the Krakow Transplant Center during 1992-2000. The analysis concerned 94 cadaveric transplant recipients. The study group included 31 females aged 23 to 61 years (mean 40.4 years) and 63 males aged 16 to 60 years (mean 41.8 years). The time of pre-transplant renal replacement therapy ranged from 4 to 120 months (mean 32 months). The mean time of total ischaemia was 22 hours 20 minutes. The majority of the recipients had three identical antigens out of six typed. Most of the recipients were treated with three immunosuppressive drugs including: Cyclosporine A, Azathioprine and steroids. Immediately after kidney transplantation 25.6% of the patients had urine output and did not require dialysis. Acute renal failure (ARF) of the graft was observed in 73.2% recipients. The average number of hemodialysis sessions in patients presenting ARF was 10. Acute rejection was diagnosed in 41.5% of the patients. The most frequent complications were: CMV (cytomegalovirus) infection, UTI (urinary tract infection) and policytemia. In the study group 1-year survival rate of the patients was 97.8% and 1-year graft survival was 93.61%. The 5-year survival rates both in the patients and the grafts were very satisfactory (96.96% and 87.7% respectively).

MeSH terms

  • Acute Kidney Injury / epidemiology
  • Acute Kidney Injury / therapy
  • Adult
  • Cytomegalovirus Infections / epidemiology
  • Disease-Free Survival
  • Female
  • Graft Rejection / epidemiology*
  • Humans
  • Immunosuppression Therapy / methods
  • Incidence
  • Kidney Transplantation / adverse effects
  • Kidney Transplantation / immunology
  • Kidney Transplantation / mortality
  • Kidney Transplantation / statistics & numerical data*
  • Male
  • Middle Aged
  • Poland / epidemiology
  • Postoperative Complications / epidemiology*
  • Renal Dialysis / statistics & numerical data*
  • Survival Rate
  • Treatment Outcome
  • Urinary Tract Infections / epidemiology